ATE229943T1 - Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen - Google Patents

Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen

Info

Publication number
ATE229943T1
ATE229943T1 AT98105754T AT98105754T ATE229943T1 AT E229943 T1 ATE229943 T1 AT E229943T1 AT 98105754 T AT98105754 T AT 98105754T AT 98105754 T AT98105754 T AT 98105754T AT E229943 T1 ATE229943 T1 AT E229943T1
Authority
AT
Austria
Prior art keywords
substituted
imidazo
amines
quinoline
production
Prior art date
Application number
AT98105754T
Other languages
English (en)
Inventor
John F Gerster
Stephen L Crooks
Kyle J Lindstrom
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of ATE229943T1 publication Critical patent/ATE229943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Lubricants (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT98105754T 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen ATE229943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292691A 1991-03-01 1991-03-01
US68732691A 1991-04-18 1991-04-18

Publications (1)

Publication Number Publication Date
ATE229943T1 true ATE229943T1 (de) 2003-01-15

Family

ID=27098631

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine
AT98105754T ATE229943T1 (de) 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine

Country Status (18)

Country Link
EP (2) EP0582581B1 (de)
JP (1) JP2955019B2 (de)
AT (2) ATE179711T1 (de)
AU (2) AU658621B2 (de)
CA (2) CA2289219C (de)
CZ (1) CZ285050B6 (de)
DE (2) DE69229114T2 (de)
DK (2) DK0872478T3 (de)
ES (2) ES2186034T3 (de)
HU (5) HU222111B1 (de)
IE (1) IE920605A1 (de)
IL (2) IL114570A (de)
NO (1) NO303729B1 (de)
NZ (1) NZ241784A (de)
PH (1) PH31614A (de)
SG (2) SG46492A1 (de)
UA (1) UA32546C2 (de)
WO (1) WO1992015582A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
JPH09500128A (ja) * 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US6133547A (en) * 1996-09-05 2000-10-17 Medtronic, Inc. Distributed activator for a two-dimensional shape memory alloy
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JPH10298181A (ja) * 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
EP1541572A1 (de) * 2000-12-08 2005-06-15 3M Innovative Properties Company Thioether substituierte Imidazochinoline
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2003259226A1 (en) * 2002-07-23 2004-02-09 Biogal Gyogyszergyar Rt Preparation of 1h-imidazo(4,5-c)quinolin-4-amines via1h-imidazo (4,5-c)quinolin-4-phthalimide intermediates
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
EP1851224A2 (de) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl-substituierte imidazochinoline
JP2008531567A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
KR20080083270A (ko) * 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
EP2382988A1 (de) 2006-03-31 2011-11-02 Novartis AG Kombinierte mukosale und parenterale Immunisierung gegen HIV
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2659733A1 (en) 2006-07-31 2008-02-07 3M Innovative Properties Company Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
EP4585610A3 (de) 2006-09-11 2025-09-24 Seqirus UK Limited Herstellung von influenzavirus-impfstoffen ohne verwendung von eiern
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
HRP20120895T1 (hr) * 2007-05-08 2012-11-30 Astrazeneca Ab Imidazokinolini sa imuno-modulacijskim svojstvima
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN102015651B (zh) * 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
DK2276486T3 (da) * 2008-03-24 2013-11-25 4Sc Discovery Gmbh Nye substituerede imidazo-quinoliner
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3263128A3 (de) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Zusammensetzungen zur immunisierung gegen staphylococcus aureus
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084726A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
EP2729178A1 (de) 2011-07-08 2014-05-14 Novartis AG Tyrosinverbindungsverfahren
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
TR201808684T4 (tr) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
CN111249455A (zh) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
WO2014120995A2 (en) * 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
CN106103469B (zh) 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
PT3134402T (pt) * 2014-04-22 2020-07-02 Hoffmann La Roche Compostos de 4-amino-imidazoquinolina
PT3265458T (pt) 2015-03-06 2019-02-13 Hoffmann La Roche Compostos de dicarboxamida de benzazepina
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
CN108055842B (zh) 2015-09-17 2021-06-29 豪夫迈·罗氏有限公司 亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
CN109311854B (zh) 2016-05-23 2021-08-10 豪夫迈·罗氏有限公司 具有仲酰胺官能团的苯并氮杂卓二甲酰胺化合物
JP6918838B2 (ja) 2016-05-23 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
JP7012668B2 (ja) 2016-06-12 2022-02-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
TWI674261B (zh) * 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
ES2928723T3 (es) * 2017-05-19 2022-11-22 Superb Wisdom Ltd Derivados de Resiquimod
CA3067268A1 (en) * 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
EP0385630B1 (de) * 1989-02-27 1996-11-27 Riker Laboratories, Inc. 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel

Also Published As

Publication number Publication date
DE69229114T2 (de) 1999-11-04
IL101110A0 (en) 1992-11-15
AU658621B2 (en) 1995-04-27
DE69232878T2 (de) 2003-11-20
IE920605A1 (en) 1992-09-09
HU222247B1 (hu) 2003-05-28
IE990988A1 (en) 2000-12-13
CZ178893A3 (en) 1995-10-18
EP0872478B1 (de) 2002-12-18
SG70625A1 (en) 2000-02-22
NO933069D0 (no) 1993-08-27
ES2131070T3 (es) 1999-07-16
HU222250B1 (hu) 2003-05-28
AU1566992A (en) 1992-10-06
CA2289219A1 (en) 1992-09-02
HU9701084D0 (en) 1997-08-28
WO1992015582A1 (en) 1992-09-17
CZ285050B6 (cs) 1999-05-12
HU9302457D0 (en) 1993-11-29
AU673309B2 (en) 1996-10-31
DK0582581T3 (da) 1999-11-08
HU222111B1 (hu) 2003-04-28
DE69232878D1 (de) 2003-01-30
IL114570A (en) 1996-10-31
DE69229114D1 (de) 1999-06-10
HU222251B1 (hu) 2003-05-28
CA2104782A1 (en) 1992-09-02
AU2715795A (en) 1995-09-21
PH31614A (en) 1999-01-12
UA32546C2 (uk) 2001-02-15
CA2289219C (en) 2003-05-20
NZ241784A (en) 1995-06-27
DK0872478T3 (da) 2003-03-31
HUT67026A (en) 1995-01-30
NO303729B1 (no) 1998-08-24
HU211242A9 (en) 1995-11-28
ES2186034T3 (es) 2003-05-01
HU9701083D0 (en) 1997-08-28
EP0872478A3 (de) 1998-11-04
JP2955019B2 (ja) 1999-10-04
CA2104782C (en) 2001-08-07
ATE179711T1 (de) 1999-05-15
JPH06504789A (ja) 1994-06-02
HU9701089D0 (en) 1997-08-28
EP0872478A2 (de) 1998-10-21
EP0582581A1 (de) 1994-02-16
SG46492A1 (en) 1998-02-20
EP0582581B1 (de) 1999-05-06
IL101110A (en) 1995-12-08
IL114570A0 (en) 1995-11-27
NO933069L (no) 1993-11-01

Similar Documents

Publication Publication Date Title
ATE229943T1 (de) Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen
DK0550113T3 (da) Triazolpyrimidinderivater med fungicid virkning
ATE18048T1 (de) Carbapenem-derivate, ihre herstellung und sie enthaltende zusammensetzungen.
NO304946B1 (no) Xantinderivat samt dets anvendelse
PT920430E (pt) Derivados de purina e sua utilizacao como anticoagulantes
CZ158295A3 (en) Substituted pyrazole per se and for treating diseases, pharmaceutical compositions based thereon and intermediates for their preparation
TW221814B (de)
AU6947401A (en) Phenylpyridazine derivatives and drugs containing the same
MY141488A (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
AU5162996A (en) Pyrazolo{1,5-a}pyrimidine derivatives
EP0551844A3 (de)
ATE139767T1 (de) Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte
DE69218718D1 (de) Pharmazeutische Zusammensetzungen die Triazole Derivate enthalten zur rektalen Verabbrechung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0872478

Country of ref document: EP

REN Ceased due to non-payment of the annual fee